Citius Oncology has announced the US commercial launch of Lymphir, its novel cancer immunotherapy for cutaneous T-cell lymphoma (CTCL).  The launch follows approval by the US Food and Drug Administration (FDA) in August 2024 for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL).  The FDA approval was based on data from a […]